Cost-Effectiveness of Once-Weekly Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in the UK

被引：0
|
作者：
Muszbek, N. [1 ]
Angdembe, A. [1 ]
Garcia-Vidal, C. [2 ]
Bielicka, I [3 ]
Abrams, K. [1 ]
Tolley, K. [4 ]
Ruhnke, M. [5 ]
Lebmeier, M.
Hawkins, N. [1 ]
Manamley, N. [3 ]
Dickerson, S. [3 ]
机构：
[1] Visible Analyt, Oxford, Oxon, England
[2] Hosp Clin Barcelona, Barcelona, Catalonia, Spain
[3] Mundipharma Res Ltd, Cambridge, Cambs, England
[4] Tolley Hlth Econ, Buxton, DBY, England
[5] Helios Klinikum Aue, Aue Bad Schlema, Sachsen, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE332
引用
下载
收藏
页码：S115 / S115
页数：1
相关论文
共 50 条
  • [21] EVALUATING THE COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS EMPAGLIFLOZIN 25 MG FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN THE UK SETTING
    Capehorn, M.
    Hallen, N.
    Hunt, B.
    VALUE IN HEALTH, 2020, 23 : S512 - S512
  • [22] Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
    Matthew Capehorn
    Nino Hallén
    James Baker-Knight
    Divina Glah
    Barnaby Hunt
    Diabetes Therapy, 2021, 12 : 537 - 555
  • [23] Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
    Capehorn, Matthew
    Hallen, Nino
    Baker-Knight, James
    Glah, Divina
    Hunt, Barnaby
    DIABETES THERAPY, 2021, 12 (02) : 537 - 555
  • [24] COST-EFFECTIVENESS ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE VERSUS POLYETHYLENE GLYCOL LOXENATIDE FOR TREATMENT OF TYPE 2 DIABETES IN CHINA
    Liu, L.
    Zhen, R.
    Ung, C. O. L.
    Shen, Y.
    Zhang, Y.
    Han, S.
    Jia, R.
    Qiao, J.
    Hu, H.
    Guo, L.
    VALUE IN HEALTH, 2022, 25 (12) : S116 - S116
  • [25] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Gu, Shuyan
    Gu, Jinghong
    Wang, Xiaoyong
    Wang, Xiaoling
    Li, Lu
    Gu, Hai
    Xu, Biao
    HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [26] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Shuyan Gu
    Jinghong Gu
    Xiaoyong Wang
    Xiaoling Wang
    Lu Li
    Hai Gu
    Biao Xu
    Health Economics Review, 14
  • [27] Novel Once-Weekly Echinocandin Rezafungin (CD101) Prevention and Treatment of Pneumocystis Biofilms
    Cushion, Melanie T.
    Collins, Margaret S.
    Locke, Jeffrey B.
    Ong, Voon
    Bartizal, Ken
    BONE MARROW TRANSPLANTATION, 2018, 53 : 574 - 574
  • [28] Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin
    Jose Gorgojo-Martinez, Juan
    Malkin, Samuel J. P.
    Martin, Virginia
    Hallen, Nino
    Hunt, Barnaby
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (02) : 193 - 203
  • [29] COST-EFFECTIVENESS OF ONCE-DAILY SOMATROPIN FROM SANDOZ VERSUS ONCE-WEEKLY SOMATROGON FOR THE TREATMENT OF GROWTH HORMONE DEFICIENCY IN CHILDREN AND ADOLESCENTS
    Mehl, A.
    Goh, A.
    Gupts, S.
    VALUE IN HEALTH, 2022, 25 (12) : S171 - S171
  • [30] PROJECTED COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS EXENATIDE BID FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK
    Wilson, B. P.
    Beaudet, A.
    Caputo, J.
    Timlin, L.
    VALUE IN HEALTH, 2011, 14 (07) : A476 - A476
12345